Lung Cancer Clinical Trials

Showing 1601-1620 of 4,288 trials

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

NCT05295212

This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.

Non Small Cell Lung Cancer

Hunan Province Tumor Hospital120 participantsStarted Feb 2023

Changsha, Hunan, China

COMPLETEDPhase 2

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

NCT02855125

This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC. The study will be conducted internationally in 2 regions: Asian \[Japan\] and Western \[Europe and US\]. Patients will be randomized into TAS-114/S-1 arm versus S-1 control arm in a 1:1 ratio.

Advanced or Metastatic Non-small Cell Lung Cancer

Taiho Oncology, Inc.128 participantsStarted Aug 2016

Loma Linda, California, United States • Gainesville, Florida, United States • Cleveland, Ohio, United States +27 more locations

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Related Searches

A Novel Lung Function Imaging Modality As a Preoperative Evaluation Tool (LIME)

Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer

Evaluation of the Contribution of a DEMaterialized VIdeo-pedagogical SUpport in the Care Pathway of Lung Cancer Surgery Patients

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis

EB-OCT Biopsy Guidance of Lung Cancer

Multidisciplinary Prehabilitation Management Pathway and Network Platform Construction

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

DECIDE: Developing Tools for Lung Cancer Screening Discussion Improvement

Comparison Between Different Ways for Using Lidocaine During FB

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)